Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trabodenoson (INO-8875) is a selective and potent adenosine A1 receptor agonist, an adenosine analog, for the study of primary open-angle glaucoma.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 75,500 | |||
10 mg | 在庫あり | ¥ 113,000 | |||
25 mg | 在庫あり | ¥ 181,000 | |||
50 mg | 在庫あり | ¥ 245,500 | |||
100 mg | 在庫あり | ¥ 328,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 83,500 |
説明 | Trabodenoson (INO-8875) is a selective and potent adenosine A1 receptor agonist, an adenosine analog, for the study of primary open-angle glaucoma. |
In vitro | Treatment with Trabodenoson significantly increases MMP-2 activity and MMP-14 abundance, while decreasing expression of fibronectin and collagen IV[2]. |
In vivo |
Trabodenoson (6.0%) demonstrates an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation)[2]. In induced eyes, topical trabodenoson significantly upregulates nestin expression in the ONH compared with vehicle-treated non-induced eyes[1]. Trabodenoson-treated eyes show significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. Additionally, RGC counts are higher in Trabodenoson-treated eyes compared to vehicle, accounting for 74% versus 47% of the contralateral eye[1]. |
別名 | INNO-8875, INO-8875, PJ875, PJ-875, INNO 8875, INNO8875, PJ 875 |
分子量 | 380.36 |
分子式 | C15H20N6O6 |
CAS No. | 871108-05-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (262.91 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Trabodenoson 871108-05-3 GPCR/G Protein Neuroscience Adenosine Receptor INNO-8875 INO-8875 PJ875 PJ-875 INNO 8875 INNO8875 PJ 875 Inhibitor inhibitor inhibit